
Claims

1. A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula I:



Formula I

wherein A is optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5 to 10-membered heteroarylene;

L^1 is absent or a linker;

W is a cross-linking group comprising a vinyl ketone, vinyl sulfone, ynone, or an alkynyl sulfone;


R^1 is hydrogen, optionally substituted 3 to 10-membered heterocycloalkyl, or optionally substituted C_1-C_6 heteroalkyl;

R^2 is optionally substituted C_1-C_6 alkyl; and

R^3 is optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_3 heteroalkyl.

2. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted thiazole, optionally substituted oxazole, optionally substituted morpholino, optionally substituted pyrrolidinyl, optionally substituted pyridyl, optionally substituted azetidinyl, optionally substituted pyrazinyl, optionally substituted pyrimidine, optionally substituted piperidinyl, optionally substituted oxadiazole, optionally substituted thiadiazole, optionally substituted triazole, optionally substituted thiomorpholino, or optionally substituted phenyl.

3. The compound of claim 1 or 2, or pharmaceutically acceptable salt thereof, wherein R^2 is:



.

4. The compound of any one of claims 1 to 3, or pharmaceutically acceptable salt thereof, wherein R^3 is optionally substituted C_1-C_6 alkyl.

5. The compound of any one of claims 1 to 3, or pharmaceutically acceptable salt thereof, wherein R^3 is optionally substituted C_1-C_3 heteroalkyl.

6. The compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted 5 to 10-membered heteroarylene.

7. The compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted phenyl.

8. The compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof, wherein A is optionally substituted 3 to 6-membered heterocycloalkylene.

9. The compound of any one of claims 1 to 8, or pharmaceutically acceptable salt thereof, wherein the linker is the structure of Formula III:


$$A^1\text{-}(B^1)_f\text{-}(C^1)_g\text{-}(B^2)_h\text{-}(D^1)\text{-}(B^3)_i\text{-}(C^2)_j\text{-}(B^4)_k\text{–}A^2$$

Formula III,

wherein A^1 is a bond between the linker and $CH(R^3)$; A^2 is a bond between W and the linker; B^1, B^2, B^3, and B^4 each, independently, is selected from optionally substituted C_1-C_2 alkylene, optionally substituted C_1-C_3 heteroalkylene, O, S, and NR^N; each R^N is, independently, hydrogen, optionally substituted C_1–C_4 alkyl, optionally substituted C_2-C_4 alkenyl, optionally substituted C_2-C_4 alkynyl, optionally substituted 3 to 14-membered heterocycloalkyl, optionally substituted 6 to 10-membered aryl, or optionally substituted C_1-C_7 heteroalkyl; C^1 and C^2 are each, independently, selected from carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; f, g, h, i, j, and k are each, independently, 0 or 1; and D^1 is optionally substituted C_1-C_{10} alkylene, optionally substituted C_2-C_{10} alkenylene, optionally substituted C_2-C_{10} alkynylene, optionally substituted 3 to 14-membered heterocycloalkylene, optionally substituted 5 to 10-membered heteroarylene, optionally substituted 3 to 8-membered cycloalkylene, optionally substituted 6 to 10-membered arylene, optionally substituted C_2-C_{10} polyethylene glycolene, or optionally substituted C_1-C_{10} heteroalkylene, or a chemical bond linking A^1-$(B^1)_f$-$(C^1)_g$-$(B^2)_h$- to -$(B^3)_i$-$(C^2)_j$-$(B^4)_k$–A^2.

10. The compound of any one of claims 1 to 9, or pharmaceutically acceptable salt thereof, wherein the linker is or comprises a cyclic moiety.

11. The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein the linker has the structure of Formula IIIa:



Formula IIIa,

wherein o is 0 or 1;









R^7 is hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted 3 to 8-membered cycloalkylene, or optionally substituted 3 to 8-membered heterocycloalkylene;











X^1 is absent, optionally substituted C_1-C_4 alkylene, O, NCH_3, or optionally substituted C_1-C_4 heteroalkylene;











Cy is optionally substituted 3 to 8-membered cycloalkylene, optionally substituted 3 to 12-membered heterocycloalkylene, optionally substituted 6-10 membered arylene, or optionally substituted 5 to 10-membered heteroarylene; and











L^2 is absent, -SO_2-, -NH-, optionally substituted C_1-C_4 alkylene, optionally substituted C_1-C_4 heteroalkylene, or optionally substituted 3 to 6-membered heterocycloalkylene.











12. The compound of any one of claims claim 1 to 11, or pharmaceutically acceptable salt thereof, wherein the compound is not a compound of Table 2 as shown hereafter:











Ex#	Structure	Ex#	Structure
B1		**B544**	
B2		**B545**	
B3		**B546**	
B4		**B547**	











Ex#	Structure	Ex#	Structure
B5		B548	
B6		B549	
B7		B550	
B8		B551	
B9		B552	











Ex#	Structure	Ex#	Structure
B10		B553	
B11		B554	
B12		B555	
B13		B556	
B14		B557	











Ex#	Structure	Ex#	Structure
B15		B558	
B16		B559	
B17		B560	
B18		B561	
B19		B562	











Ex#	Structure	Ex#	Structure
B20		B563	
B21		B564	
B22		B565	
B23		B566	
B24		B567	











Ex#	Structure	Ex#	Structure
B25		B568	
B26		B569	
B27		B570	
B28		B571	
B29		B572	











Ex#	Structure	Ex#	Structure
B30		B573	
B31		B574	
B32		B575	
B33		B576	
B34		B577	











Ex#	Structure	Ex#	Structure
B35		B578	
B36		B579	
B37		B580	
B38		B581	
B39		B582	











Ex#	Structure	Ex#	Structure
B40		B583	
B41		B584	
B42		B585	
B43		B586	
B44		B587	











Ex#	Structure	Ex#	Structure
B45		B588	
B46		B589	
B47		B590	
B48		B591	
B49		B592	











Ex#	Structure	Ex#	Structure
B50		B593	
B51		B594	
B52		B595	
B53		B596	
B54		B597	











Ex#	Structure	Ex#	Structure
B55		B598	
B56		B599	
B57		B600	
B58		B601	
B59		B602	











Ex#	Structure	Ex#	Structure
B60		B603	
B61		B604	
B62		B605	
B63		B606	
B64		B607	











Ex#	Structure	Ex#	Structure
B65		B608	
B66		B609	
B67		B610	
B68		B611	
B69		B612	











Ex#	Structure	Ex#	Structure
B70		B613	
B71		B614	
B72		B615	
B73		B616	
B74		B617	











Ex#	Structure	Ex#	Structure
B75		B618	
B76		B619	
B77		B620	
B78		B621	
B79		B622	











Ex#	Structure	Ex#	Structure
B80		B623	
B81		B624	
B82		B625	
B83		B626	
B84		B627	











Ex#	Structure	Ex#	Structure
B85		B628	
B86		B629	
B87		B630	
B88		B631	
B89		B632	











Ex#	Structure	Ex#	Structure
B90		B633	
B91		B634	
B92		B635	
B93		B636	
B94		B637	











Ex#	Structure	Ex#	Structure
B95		B638	
B96		B639	
B97		B640	
B98		B641	
B99		B642	











Ex#	Structure	Ex#	Structure
B100		B643	
B101		B644	
B102		B645	
B103		B646	
B104		B647	











Ex#	Structure	Ex#	Structure
B105		B648	
B106		B649	
B107		B650	
B108		B651	
B109		B652	











Ex#	Structure	Ex#	Structure
B110		B653	
B111		B654	
B112		B655	
B113		B656	
B114		B657	











Ex#	Structure	Ex#	Structure
B115		B658	
B116		B659	
B117		B660	
B118		B661	
B119		B662	











Ex#	Structure	Ex#	Structure
B120		B663	
B121		B664	
B122		B665	
B123		B666	
B124		B667	











Ex#	Structure	Ex#	Structure
B125		B668	
B126		B669	
B127		B670	
B128		B671	
B129		B672	











Ex#	Structure	Ex#	Structure
B130		B673	
B131		B674	
B132		B675	
B133		B676	
B134		B677	











Ex#	Structure	Ex#	Structure
B135		B678	
B136		B679	
B137		B680	
B138		B681	
B139		B682	











Ex#	Structure	Ex#	Structure
B140		B683	
B141		B684	
B142		B685	
B143		B686	
B144		B687	











Ex#	Structure	Ex#	Structure
B145		B688	
B146		B689	
B147		B690	
B148		B691	
B149		B692	











Ex#	Structure	Ex#	Structure
B150		B693	
B151		B694	
B152		B695	
B153		B696	
B154		B697	











Ex#	Structure	Ex#	Structure
B155		B698	
B156		B699	
B157		B700	
B158		B701	
B159		B702	











Ex#	Structure	Ex#	Structure
B160		B703	
B161		B704	
B162		B705	
B163		B706	
B164		B707	











Ex#	Structure	Ex#	Structure
B165		B708	
B166		B709	
B167		B710	
B168		B711	
B169		B712	













Ex#	Structure	Ex#	Structure
B170		B713	
B171		B714	
B172		B715	
B173		B716	
B174		B717	













Ex#	Structure	Ex#	Structure
B175		B718	
B176		B719	
B177		B720	
B178		B721	
B179		B722	













Ex#	Structure	Ex#	Structure
B180		B723	
B181		B724	
B182		B725	
B183		B726	
B184		B727	













Ex#	Structure	Ex#	Structure
B185		B728	
B186		B729	
B187		B730	
B188		B731	
B189		B732	













Ex#	Structure	Ex#	Structure
B190		B733	
B191		B734	
B192		B735	
B193		B736	
B194		B737	








Ex#	Structure	Ex#	Structure
B195		B738	
B196		B739	
B197		B740	
B198		B741	
B199		C1	
B200		C2	













Ex#	Structure	Ex#	Structure
B201		C3	
B202		C4	
B203		C5	
B204		C6	
B205		C7	
B206		C11	













Ex#	Structure	Ex#	Structure
B207		C12	
B208		C13	
B209		C18	
B210		C21	
B211		C22	
B212		C25	















Ex#	Structure	Ex#	Structure
B213		C27	
B214		C28	
B215		C29	
B216		C30	
B217		C32	
B218		C34	















Ex#	Structure	Ex#	Structure
B219		C38	
B220		C47	
B221		C64	
B222		C65	
B223		C66	
B224		C70	















Ex#	Structure	Ex#	Structure
B225		C73	
B226		C74	
B227		C75	
B228		C76	
B229		C77	
B230		C81	















Ex#	Structure	Ex#	Structure
B231		C83	
B232		C85	
B233		C86	
B234		C87	
B235		C88	
B236		C89	













Ex#	Structure	Ex#	Structure
B237		C90	
B238		C91	
B239		C96	
B240		C97	
B241		C102	
B242		C103	













Ex#	Structure	Ex#	Structure
B243		C104	
B244		C106	
B245		C107	
B246		C109	
B247		C111	
B248		C112	
B249		C113	













Ex#	Structure	Ex#	Structure
B250		C115	
B251		C116	
B252		C117	
B253		C118	
B254		C119	
B255		C120	
B256		C121	













Ex#	Structure	Ex#	Structure
B257		C122	
B258		C123	
B259		C124	
B260		C126	
B261		C127	
B262		C128	
B263		C129	













Ex#	Structure	Ex#	Structure
B264		C130	
B265		C131	
B266		C132	
B267		C139	
B268		C140	
B269		C141	
B270		C142	















Ex#	Structure	Ex#	Structure
B271		C143	
B272		C144	
B273		C145	
B274		C146	
B275		C147	
B276		C148	













Ex#	Structure	Ex#	Structure
B277		C149	
B278		C150	
B279		C161	
B280		C162	
B281		C163	
B282		C164	













Ex#	Structure	Ex#	Structure
B283		C165	
B284		C167	
B285		C168	
B286		C169	
B287		C170	
B288		C171	













Ex#	Structure	Ex#	Structure
B289		C172	
B290		C173	
B291		C174	
B292		C175	
B293		C176	
B294		C177	













Ex#	Structure	Ex#	Structure
B295		C178	
B296		C179	
B297		C180	
B298		C181	
B299		C182	
B300		C183	













Ex#	Structure	Ex#	Structure
B301		C184	
B302		C185	
B303		C186	
B304		C187	
B305		C188	
B306		C189	
B307		C190	













Ex#	Structure	Ex#	Structure
B308		C191	
B309		C192	
B310		C194	
B311		C195	
B312		C196	
B313		C197	











Ex#	Structure	Ex#	Structure
B314		C198	
B316		C199	
B317		C200	
B318		C201	
B319		C202	
B320		C203	













Ex#	Structure	Ex#	Structure
B321		C204	
B322		C205	
B323		C206	
B324		C207	
B325		C208	
B326		C209	










Ex#	Structure	Ex#	Structure
B327		C210	
B328		C211	
B329		C212	
B330		C213	
B331		C214	
B332		C215	











Ex#	Structure	Ex#	Structure
B333		C216	
B334		C217	
B335		C218	
B336		C219	
B337		C220	
B338		C221	











Ex#	Structure	Ex#	Structure
B339		C222	
B340		C223	
B341		C224	
B342		C225	
B343		C226	
B344		C227	










Ex#	Structure	Ex#	Structure
B345		C228	
B346		C229	
B347		C230	
B348		C231	
B349		C232	










Ex#	Structure	Ex#	Structure
B350		C233	
B351		C234	
B352		C235	
B353		C236	
B354		C237	
B355		C238	











Ex#	Structure	Ex#	Structure
B356		C239	
B357		C240	
B358	 	C241	
B359		C242	











Ex#	Structure	Ex#	Structure
B360		C243	
B361		C244	
B362		C245	
B363		C246	
B364		C247	











Ex#	Structure	Ex#	Structure
B365		C248	
B366		C249	
B367		C250	
B368		C251	
B369		C252	











Ex#	Structure	Ex#	Structure
B370		C253	
B371		C254	
B372		C255	
B373	 	C256	










Ex#	Structure	Ex#	Structure
B374		C257	
B375		C258	
B376		C259	
B377	 	C260	











Ex#	Structure	Ex#	Structure
B378		C261	
B379		C262	
B380		C263	
B381		C264	
B382		C265	











Ex#	Structure	Ex#	Structure
B383		C266	
B384		C267	
B385		C268	
B386		C269	
B387		C270	











Ex#	Structure	Ex#	Structure
B388		C271	
B389		C272	
B390		C273	
B391		C274	
B392		C275	











Ex#	Structure	Ex#	Structure
B393		C276	
B394		C277	
B395		C278	
B396		C279	
B397		C280	











Ex#	Structure	Ex#	Structure
B398		C282	
B399	 	C283	
B400		C284	
B401		C285	











Ex#	Structure	Ex#	Structure
B402		C286	
B403		C287	
B404		C288	
B405		C289	
B406		C290	











Ex#	Structure	Ex#	Structure
B407		C291	
B408		C292	
B409		C293	
B410		C294	
B411		C295	











Ex#	Structure	Ex#	Structure
B412		C296	
B413		C297	
B414		C298	
B415		C299	
B416		C300	













Ex#	Structure	Ex#	Structure
B417		C301	
B418		C302	
B419		C303	
B420		C304	
B421		C305	











Ex#	Structure	Ex#	Structure
B422		C306	
B423		C307	
B424		C308	
B425		C309	
B426		C310	











Ex#	Structure	Ex#	Structure
B427		C311	
B428		C312	
B429		C313	
B430		C314	
B431		C315	











Ex#	Structure	Ex#	Structure
B432		C316	
B433		C317	
B334		C318	
B435		C319	
B436		C320	











Ex#	Structure	Ex#	Structure
B437		C321	
B438		C322	
B439		C323	
B440		C324	
B441		C325	











Ex#	Structure	Ex#	Structure
B442		C326	
B443		C327	
B444		C328	
B445		C329	
B446		C330	
B447		C331	











Ex#	Structure	Ex#	Structure
B448		C332	
B449		C333	
B450		C334	
B451		C335	
B452		C336	











Ex#	Structure	Ex#	Structure
B453		C337	
B454		C338	
B455		C339	
B456		C340	
B457		C341	











Ex#	Structure	Ex#	Structure
B458		C342	
B459		C343	
B460		C344	
B461		C345	
B462		C346	











Ex#	Structure	Ex#	Structure
B463		C347	
B464		C348	
B465		C349	
B466		C350	
B467		C351	











Ex#	Structure	Ex#	Structure
B468		C352	
B469		C353	
B470		C354	
B471		C355	
B472		C356	











Ex#	Structure	Ex#	Structure
B473		C357	
B474		C358	
B475		C359	
B476		C360	
B477		C361	











Ex#	Structure	Ex#	Structure
B478		C362	
B479		C363	
B480		C364	
B481		C365	
B482		C366	











Ex#	Structure	Ex#	Structure
B483		C367	
B484		C368	
B485		C369	
B486		C370	
B487		C371	











Ex#	Structure	Ex#	Structure
B488		C372	
B489		C373	
B490		C374	
B491		C375	
B492		C376	













Ex#	Structure	Ex#	Structure
B493		C377	
B494		C378	
B495		C379	
B496		C380	
B497		C381	











Ex#	Structure	Ex#	Structure
B498		C382	
B499		C383	
B500		C384	
B501		C385	
B502		C386	











Ex#	Structure	Ex#	Structure
B503		C387	
B504		C388	
B505		C389	
B506		C390	
B507		C391	













Ex#	Structure	Ex#	Structure
B508		C392	
B509		C393	
B510		C394	
B511		C395	
B512		C396	







Ex#	Structure	Ex#	Structure
B513		C397	
B514		C398	
B515		C399	
B516		C400	
B517		C401	

Ex#	Structure	Ex#	Structure
B518		C402	
B519		C403	
B520		C404	
B521		C405	
B522		C406	
B523		C407	

Ex#	Structure	Ex#	Structure
B524		C408	
B525		C409	
B526		C410	
B527		C411	
B528		C412	


Ex#	Structure	Ex#	Structure
B529		C413	
B530		C414	
B531		C415	
B532		C416	
B533		C417	

Ex#	Structure	Ex#	Structure
B534		C418	
B535		C419	
B536		C420	
B537		C421	
B538		C422	
B539		C423	

Ex#	Structure	Ex#	Structure
B540		C424	
B541		C425	
B542			
B543			

.

13. The compound of any one of claims 1 to 12, or pharmaceutically acceptable salt thereof, having the structure of Formula II-5:



Formula II-5,

wherein Cy^1 is optionally substituted spirocyclic 8 to 11-membered heterocycloalkylene or optionally substituted bicyclic 7 to 9-membered heterocycloalkylene; and


wherein W comprises a vinyl ketone or a vinyl sulfone.

14. The compound of any one of claims 1 to 13, or pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising a vinyl ketone.

15. The compound of any one of claims 1 to 13, or pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising a vinyl sulfone.

16. The compound of any one of claims 1 to 13, or pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising an ynone.

17. The compound of claim 16, or pharmaceutically acceptable salt thereof, having the structure of Formula II-6:



Formula II-6,





wherein Q^1 is CH_2, NR^N, or O;











Q^2 is CO, NR^N, or O; and











Z is optionally substituted 3 to 6-membered heterocycloalkylene or optionally substituted 5 to 10-membered heteroarylene; or











wherein Q^1-Q^2-Z is an optionally substituted 9 to 10-membered spirocyclic heterocycloalkylene.











18. A compound, or a pharmaceutically acceptable salt thereof, selected from Table 1 as shown hereafter:











Ex#	Structure	Ex#	Structure
A1		**A105**	
A2		**A106**	











Ex#	Structure	Ex#	Structure
A3		A107	
A4		A108	
A5		A109	
A6		A110	
A7		A111	











Ex#	Structure	Ex#	Structure
A8		A112	
A9		A113	
A10		A114	
A11		A115	
A12		A116	











Ex#	Structure	Ex#	Structure
A13		A117	
A14		A118	
A15		A119	
A16		A120	
A17		A121	











Ex#	Structure	Ex#	Structure
A18		A122	
A19		A123	
A20		A124	
A21		A125	
A22		A126	











Ex#	Structure	Ex#	Structure
A23		A127	
A24		A128	
A25		A129	
A26		A130	
A27		A131	











Ex#	Structure	Ex#	Structure
A28		A132	
A29		A133	
A30		A134	
A31		A135	
A32		A136	











Ex#	Structure	Ex#	Structure
A33		A137	
A34		A138	
A35		A139	
A36		A140	
A37		A141	











Ex#	Structure	Ex#	Structure
A38		A142	
A39		A143	
A40		A144	
A41		A145	
A42		A146	











Ex#	Structure	Ex#	Structure
A43		A147	
A44		A148	
A45		A149	
A46		A150	
A47		A151	











Ex#	Structure	Ex#	Structure
A48		A152	
A49		A153	
A50		A154	
A51		A155	
A52		A156	











Ex#	Structure	Ex#	Structure
A53		A157	
A54		A158	
A55		A159	
A56		A160	
A57		A161	











Ex#	Structure	Ex#	Structure
A58		A162	
A59		A163	
A60		A164	
A61		A165	
A62		A166	











Ex#	Structure	Ex#	Structure
A63		A167	
A64		A168	
A65		A169	
A66		A170	
A67		A171	











Ex#	Structure	Ex#	Structure
A68		A172	
A69		A173	
A70		A174	
A71		A175	
A72		A176	













Ex#	Structure	Ex#	Structure
A73		A177	
A74		A178	
A75		A179	
A76		A180	
A77		A181	





Ex#	Structure	Ex#	Structure
A78		A182	
A79		A183	
A80		A184	
A81		A185	
A82		A186	

Ex#	Structure	Ex#	Structure
A83		A187	
A84		A188	
A85		A189	
A86		A190	
A87		A191	

Ex#	Structure	Ex#	Structure
A88		A192	
A89		A193	
A90		A194	
A91		A195	
A92		A196	

Ex#	Structure	Ex#	Structure
A93		A197	
A94		A198	
A95		A199	
A96		A200	
A97		A201	

Ex#	Structure	Ex#	Structure
A98		A202	
A99		A203	
A100		A204	
A101		A205	
A102		A206	
A103		A207	

Ex#	Structure	Ex#	Structure
A104		A208	
A105		A209	

.

19. A pharmaceutical composition comprising a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

20. A conjugate, or salt thereof, comprising the structure of Formula V:


M-L-P

Formula V,

wherein L is a linker;

P is a monovalent organic moiety; and

M has the structure of Formula VIa:



Formula VIa,

wherein A is optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5 to 10-membered heteroarylene;

R^2 is optionally substituted C_1-C_6 alkyl;

R^3 is optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_3 heteroalkyl;

X^2 is O, $C(R^{11})_2$, NR^{12}, S, or SO_2;

r is 1 or 2;

each t is, independently, 0, 1, or 2;

R^{11} and R^{12} are each, independently, hydrogen, optionally substituted C_1-C_4 alkyl, optionally substituted C_2-C_4 heteroalkyl, or optionally substituted 3 to 5-membered cycloalkyl;

each R^{13} is, independently, $-CH_3$; and

R^4, R^5, and R^6 are each independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 6-membered heterocycloalkyl; or

R^4 and R^5 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl; or

R^4 and R^6 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl.

21. A conjugate, or salt thereof, comprising the structure of Formula V:


M-L-P

Formula V,

wherein L is a linker;

P is a monovalent organic moiety; and

M has the structure of Formula VIb:



Formula VIb,

wherein A is optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5 to 10-membered heteroarylene;

R^2 is optionally substituted C_1-C_6 alkyl;

R^3 is optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_3 heteroalkyl;

R^{14} is fluoro, hydrogen, or C_1-C_3 alkyl;

u is 0 or 1; and

R^4, R^5, and R^6 are each independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 6-membered heterocycloalkyl; or

R^4 and R^5 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl; or

R^4 and R^6 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl.

22. A conjugate, or salt thereof, comprising the structure of Formula V:


M-L-P

Formula V,

wherein L is a linker;

P is a monovalent organic moiety; and

M has the structure of Formula VIc:



Formula VIc,

wherein A is optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5 to 10-membered heteroarylene;

R^2 is optionally substituted C_1-C_6 alkyl;

R^3 is optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_3 heteroalkyl; and

R^4, R^5, and R^6 are each independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 6-membered heterocycloalkyl; or

R^4 and R^5 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl; or

R^4 and R^6 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl.

23. A conjugate, or salt thereof, comprising the structure of Formula V:


M-L-P

Formula V,

wherein L is a linker;

P is a monovalent organic moiety; and

M has the structure of Formula VId:



Formula VId,

wherein A is optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5 to 10-membered heteroarylene;

R^2 is optionally substituted C_1-C_6 alkyl;

R^3 is optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_3 heteroalkyl; and

R^4, R^5, and R^6 are each independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 6-membered heterocycloalkyl; or

R^4 and R^5 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl; or

R^4 and R^6 combine with the atoms to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or an optionally substituted 3 to 8-membered heterocycloalkyl.

24. Use of a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19, in the manufacture of a medicament for treating cancer.

25. Use of a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19, in the manufacture of a medicament for treating a Ras protein-related disorder in a subject in need thereof.

26. An *in vitro* or *ex vivo* method of inhibiting a Ras protein in a cell, the method comprising contacting the cell with an effective amount of a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19.

27. A compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19, for use in therapy.